Synonym
ACC-9653; ACC-9653; ACC9653; Fosphenytoin Sodium; Cerebyx; Pro-Epanutin; HMPDP; Prodilantin;
IUPAC/Chemical Name
disodium;(2,5-dioxo-4,4-diphenylimidazolidin-1-yl)methyl phosphate
InChi Key
GQPXYJNXTAFDLT-UHFFFAOYSA-L
InChi Code
InChI=1S/C16H15N2O6P.2Na/c19-14-16(12-7-3-1-4-8-12,13-9-5-2-6-10-13)17-15(20)18(14)11-24-25(21,22)23;;/h1-10H,11H2,(H,17,20)(H2,21,22,23);;/q;2*+1/p-2
SMILES Code
C1=CC=C(C=C1)C2(C(=O)N(C(=O)N2)COP(=O)([O-])[O-])C3=CC=CC=C3.[Na+].[Na+]
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
|
Solvent |
mg/mL |
mM |
| Solubility |
| DMSO |
90.5 |
222.77 |
| Water |
81.0 |
199.39 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
406.24
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Kaucher KA, Acquisto NM, Rao GG, Kaufman DC, Huntress JD, Forrest A, Haas CE.
Relative bioavailability of orally administered fosphenytoin sodium injection
compared with phenytoin sodium injection in healthy volunteers. Pharmacotherapy.
2015 May;35(5):482-8. doi: 10.1002/phar.1589. PubMed PMID: 26011141.
2: Inoue Y, Usui N, Hiroki T, Shimizu K, Kobayashi S, Shimasaki S.
Bioavailability of intravenous fosphenytoin sodium in healthy Japanese
volunteers. Eur J Drug Metab Pharmacokinet. 2013 Jun;38(2):139-48. doi:
10.1007/s13318-012-0105-x. Epub 2012 Sep 12. PubMed PMID: 22968854; PubMed
Central PMCID: PMC3664181.
3: Tanaka J, Kasai H, Shimizu K, Shimasaki S, Kumagai Y. Population
pharmacokinetics of phenytoin after intravenous administration of fosphenytoin
sodium in pediatric patients, adult patients, and healthy volunteers. Eur J Clin
Pharmacol. 2013 Mar;69(3):489-97. doi: 10.1007/s00228-012-1373-8. Epub 2012 Aug
24. PubMed PMID: 22918614; PubMed Central PMCID: PMC3572369.
4: Voytko SM, Farrington E. Fosphenytoin sodium: new drug to replace intravenous
phenytoin sodium. Pediatr Nurs. 1997 Sep-Oct;23(5):503-6. PubMed PMID: 9355589.
5: Fischer JH, Cwik MJ, Luer MS, Sibley CB, Deyo KL. Stability of fosphenytoin
sodium with intravenous solutions in glass bottles, polyvinyl chloride bags, and
polypropylene syringes. Ann Pharmacother. 1997 May;31(5):553-9. PubMed PMID:
9161647.
6: Fierro LS, Savulich DH, Benezra DA. Safety of fosphenytoin sodium. Am J Health
Syst Pharm. 1996 Nov 15;53(22):2707-12. Review. PubMed PMID: 8931812.
